期刊文献+

累及皮肤的结节病35例临床分析 被引量:2

The clinical analysis of 35 patients with cutaneous sarcoidosis
原文传递
导出
摘要 目的 总结分析累及皮肤的结节病的临床特点.方法 回顾性分析北京协和医院1980-2009年35例累及皮肤的结节病患者的临床资料,按有无皮肤外其他系统受累分为单纯皮肤结节病组(简称皮肤组)与合并其他系统受累的皮肤结节病组(简称系统组).结果 (1)35例患者男女之比1:3.38,发病年龄(47.5±10.0)岁,皮肤组(41.8±12.5)岁,系统组(50.5±7.1)岁.(2)皮肤损害分布以四肢最为多见,皮肤损害类型以皮下结节最为多见,其次是斑丘疹和结节红斑.(3)皮肤外系统受累以肺、关节和淋巴结最为多见,与国外全身结节病资料相比,肺受累率偏低,而关节、淋巴结、肾脏、肌肉、神经系统受累率较高.(4)在系统组中,乏力和体重减轻的发生率明显高于皮肤组(P<0.05);ESR、C反应蛋白、类风湿因子高于皮肤组(P<0.05).系统组患者糖皮质激素的使用率(95.7%)高于皮肤组(66.7%,P<0.05).结论 累及皮肤的结节病皮肤损害以皮下结节最为多见,肺受累率低,有系统受累者平均发病年龄、炎性指标水平及糖皮质激素使用率均较无系统受累者高. Objective To investigate clinical features of cutaneous sarcoidosis. Methods A retrospective analysis was carried out based on the clinic data of 35 patients with cutaneous sarcoidosis who were hospitalized in Peking Union Medical College Hospital during 1980-2009. They were divided into two groups, the group without systemic involvement (skin group )and the group with systemic involvement ( systemic group). Results ( 1 ) The ratio of men and women with cutaneous sarcoidosis was 1: 3. 38, and the average incident age was (47. 5 ± 10. 0) years old. The average incident age of skin group and systemic group were (41.8 ± 12.5 ) years old and ( 50. 5 ± 7. 1 ) years old, respectively. (2) The most common skin manifestation was subcutaneous nodule, followed by maculopapule and erythema nodosa. The most common involved sites were limbs. (3) The common involved systems extra-skin included the lung, joints and lymph nodes. The involvement rate of lung in cutaneous sarcoidosis of our present data was lower than those of foreign reports. However, the involvement rates of joints, lymph nodes, kidney, muscles and nervous system showed higher in our data. (4) The incidences of fatigue and weight loss in systemic group were higher than those in skin group ( P 〈 0. 05 ). The indexes of erythrocyte sedimentation rate, C-reactive protein and rheumatoid factor in systemic group were higher than those in skin group ( P 〈 0. 05 ). More patients in systemic group were treated with corticosteroid than that in skin group ( 95.7% vs 66.7%, P 〈 0. 05 ).Conclusions Subcutaneous nodules are the most common and the involvement rate of lung is lower in cutaneous sarcoidosis of our present data. Compared to the patients without systemic involvement, the average incident age of systemic ones is older, the indexes of inflammation markers and the usage of corticosteroid are higher.
出处 《中华内科杂志》 CAS CSCD 北大核心 2011年第5期397-400,共4页 Chinese Journal of Internal Medicine
关键词 结节病 皮肤 系统受累 临床分析 Sarcoidosis Skin Systemic involvement Clinical analysis
  • 相关文献

参考文献14

  • 1Nunes H,Bouvry D,Soler P,et al.Sarcoidosis.Orphanet J Rare Dis,2007,2:46.
  • 2English JC 3rd,Patel PJ,Greer KE.Sarcoidosis.J Am Acad Dermatol,2001,44:725-743.
  • 3Cavazza A,Harari S,Caminati A,et al.The histology of pulmonary sarcoidosis:a review with particular emphasis on unusual and underrecognized features.Int J Surg Pathol,2009,17:219-230.
  • 4Morimoto T,Azuma A,Abe S,et al.Epidemiology of sarcoidosis in Japan.Eur Respir J,2008,31:372-379.
  • 5Baughman RP,Teirstein AS,Judson MA,et al.Clinical characteristics of patients in a case control study of sarcoidosis.Am J Respir Crit Care Med,2001,164(10 Pt 1):1885-1889.
  • 6Gurkan OU,Celik G,Kumbasar O,et al.Sarcoidosis in Turkey:1954-2000.Ann Saudi Med,2004,24:36-39.
  • 7De Vries J,Lower EE,Drent M.Quality of life in sarcoidosis:assessment and management.Semin Respir Crit Care Med,2010,31:485-493.
  • 8Baughman RP,Sparkman BK,Lower EE.Six-minute walk test and health status assessment in sarcoidosis.Chest,2007,132:207-213.
  • 9Marchell RM,Judson MA.Cutaneous sarcoidosis.Semin Respir Crit Care Med,2010,31:442-451.
  • 10Baughman RP,Lower EE,Kaufman AH.Ocular sarcoidosis.Semin Respir Crit Care Med,2010,31:452-462.

同被引文献15

  • 1结节病诊断及治疗方案(第三次修订稿草案)[J].中华结核和呼吸杂志,1994,17(1):9-10. 被引量:149
  • 2李东升,姜一化,陈柳青.皮下结节型结节病一例[J].中华皮肤科杂志,2007,40(6):385-385. 被引量:2
  • 3Nguyen YT, Dupuy A, Cordoliani F, et al. Treatment of cutaneoussarcoidosis with thalidomide. J Am Acad Dermatol, 2004, 50(2):235-241.
  • 4Marchell RM, Thiers B, Judson MA. Sarcoidosis.//Wolff K,Goldsmith LA, Katz SI, et al. Fitzpatrick's Dermatology in Gen- eral Medicine. 7th ed. McGraw-Hill, New York, 2008. 1484- 1493.
  • 5Lodha S, Sanehez M, Prystowsky S. Sareoidosis of the skin: a review for the pulmonologist. Chest ,2009.136(2) :583-596.
  • 6Marehell RM, Judson MA. Cutaneous sareoidosis. Semin Respir Crit Care Med,2010,31(4) :442-451.
  • 7Hunninghake GW, Costabel U, Ando M, et al. ATS/ERS/WA- SOG statement on sareoidosis. American thoracic society/europe- an respiratory society/world association of sarcoidosis and other granulomatous disorders. Sarcoidosis Vasc Diffuse Lung Dis, 1999,16 (2) : 149-173.
  • 8Wu MC, Lee JY. Cutaneous sarcoidosis in southern Taiwan: clinicopathologic study of a series with high proportions of lesions confined to the face and angiolupoid variant. J Eur Acad Derma- tol Venereol, 2012,20 (2) : 121-124.
  • 9Varron L, Cottin V, Schott AM, et al. Late-onset sarcoidosis : a comparative study. Medicine ( Baltimore ), 2012,91 ( 3 ) : 137 - 143.
  • 10Badgwell C, Rosen T. Cutaneous sarcoidosis therapy updated. J Am Acad Dermatol,2007,56(1) :69-83.

引证文献2

二级引证文献5

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部